Search Results - "Horenstein, Richard"

Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome by Zupancic, Margaret L, Cantarel, Brandi L, Liu, Zhenqiu, Drabek, Elliott F, Ryan, Kathleen A, Cirimotich, Shana, Jones, Cheron, Knight, Rob, Walters, William A, Knights, Daniel, Mongodin, Emmanuel F, Horenstein, Richard B, Mitchell, Braxton D, Steinle, Nanette, Snitker, Soren, Shuldiner, Alan R, Fraser, Claire M

“…Obesity has been linked to the human gut microbiota; however, the contribution of gut bacterial species to the obese phenotype remains controversial because of…”
Get full text

Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism by Reyes-Soffer, Gissette, Sztalryd, Carol, Horenstein, Richard B, Holleran, Stephen, Matveyenko, Anastasiya, Thomas, Tiffany, Nandakumar, Renu, Ngai, Colleen, Karmally, Wahida, Ginsberg, Henry N, Ramakrishnan, Rajasekhar, Pollin, Toni I

“…OBJECTIVE—Apo (apolipoprotein) CIII inhibits lipoprotein lipase (LpL)-mediated lipolysis of VLDL (very-low-density lipoprotein) triglyceride (TG) and decreases…”
Get full text

A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing by Kimmel, Stephen E, French, Benjamin, Kasner, Scott E, Johnson, Julie A, Anderson, Jeffrey L, Gage, Brian F, Rosenberg, Yves D, Eby, Charles S, Madigan, Rosemary A, McBane, Robert B, Abdel-Rahman, Sherif Z, Stevens, Scott M, Yale, Steven, Mohler, Emile R, Fang, Margaret C, Shah, Vinay, Horenstein, Richard B, Limdi, Nita A, Muldowney, James A.S, Gujral, Jaspal, Delafontaine, Patrice, Desnick, Robert J, Ortel, Thomas L, Billett, Henny H, Pendleton, Robert C, Geller, Nancy L, Halperin, Jonathan L, Goldhaber, Samuel Z, Caldwell, Michael D, Califf, Robert M, Ellenberg, Jonas H

“…In this trial, 1015 patients were assigned to the use of either a genotype-guided algorithm or a clinically guided algorithm for warfarin dosing during the…”
Get full text

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy by Shuldiner, Alan R, O’Connell, Jeffrey R, Bliden, Kevin P, Gandhi, Amish, Ryan, Kathleen, Horenstein, Richard B, Damcott, Coleen M, Pakyz, Ruth, Tantry, Udaya S, Gibson, Quince, Pollin, Toni I, Post, Wendy, Parsa, Afshin, Mitchell, Braxton D, Faraday, Nauder, Herzog, William, Gurbel, Paul A

“…CONTEXT Clopidogrel therapy improves cardiovascular outcomes in patients with acute coronary syndromes and following percutaneous coronary intervention by…”
Get full text

Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection by Pollin, Toni I, Damcott, Coleen M, Shen, Haiqing, Ott, Sandra H, Shelton, John, Horenstein, Richard B, Post, Wendy, McLenithan, John C, Bielak, Lawrence F, Peyser, Patricia A, Mitchell, Braxton D, Miller, Michael, O'Connell, Jeffrey R, Shuldiner, Alan R

“…Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study,…”
Get full text

Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications by Yang, Rong-Ze, Lee, Mi-Jeong, Hu, Hong, Pollin, Toni I, Ryan, Alice S, Nicklas, Barbara J, Snitker, Soren, Horenstein, Richard B, Hull, Kristen, Goldberg, Nelson H, Goldberg, Andrew P, Shuldiner, Alan R, Fried, Susan K, Gong, Da-Wei

“…Obesity is associated with low-grade chronic inflammation, and serum markers of inflammation are independent risk factors for cardiovascular disease (CVD)…”
Get full text

Null Mutation in Hormone-Sensitive Lipase Gene and Risk of Type 2 Diabetes by Albert, Jessica S, Yerges-Armstrong, Laura M, Horenstein, Richard B, Pollin, Toni I, Sreenivasan, Urmila T, Chai, Sumbul, Blaner, William S, Snitker, Soren, O'Connell, Jeffrey R, Gong, Da-Wei, Breyer, Richard J, Ryan, Alice S, McLenithan, John C, Shuldiner, Alan R, Sztalryd, Carole, Damcott, Coleen M

“…A null mutation in the gene encoding hormone-sensitive lipase causes type 2 diabetes and results in small adipocytes, lipolysis, insulin resistance, and…”
Get full text

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response by Lewis, Joshua P, Horenstein, Richard B, Ryan, Kathleen, O’Connell, Jeffrey R, Gibson, Quince, Mitchell, Braxton D, Tanner, Keith, Chai, Sumbul, Bliden, Kevin P, Tantry, Udaya S, Peer, Cody J, Figg, William D, Spencer, Shawn D, Pacanowski, Michael A, Gurbel, Paul A, Shuldiner, Alan R

“…INTRODUCTIONCarboxylesterase 1 (CES1) is the primary enzyme responsible for converting clopidogrel into biologically inactive carboxylic acid metabolites…”
Get full text

Implementation of pharmacogenetics: The University of Maryland personalized anti-platelet pharmacogenetics program by Shuldiner, Alan R., Palmer, Kathleen, Pakyz, Ruth E., Alestock, Tameka D., Maloney, Kristin A., O'Neill, Courtney, Bhatty, Shaun, Schub, Jamie, Overby, Casey Lynnette, Horenstein, Richard B., Pollin, Toni I., Kelemen, Mark D., Beitelshees, Amber L., Robinson, Shawn W., Blitzer, Miriam G., McArdle, Patrick F., Brown, Lawrence, Jeng, Linda Jo Bone, Zhao, Richard Y., Ambulos, Nicholas, Vesely, Mark R.

“…Despite a substantial evidence base, implementation of pharmacogenetics into routine patient care has been slow due to a number of non‐trivial practical…”
Get full text

Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes) by Magvanjav, Oyunbileg, McDonough, Caitrin W, Gong, Yan, McClure, Leslie A, Talbert, Robert L, Horenstein, Richard B, Shuldiner, Alan R, Benavente, Oscar R, Mitchell, Braxton D, Johnson, Julie A

“…BACKGROUND AND PURPOSE—Functional polymorphisms (Ser49Gly and Arg389Gly) in ADRB1 have been associated with cardiovascular and β-blocker response outcomes…”
Get full text

A systematic analysis and comparison of warfarin initiation strategies by French, Benjamin, Wang, Le, Gage, Brian F, Horenstein, Richard B, Limdi, Nita A, Kimmel, Stephen E

“…OBJECTIVERandomized trials have reported inconsistent evidence on the effectiveness of algorithms that use genotypes to initiate warfarin therapy. The…”
Get full text

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) by Bergmeijer, Thomas O., Reny, Jean-Luc, Pakyz, Ruth E., Gong, Li, Lewis, Joshua P., Kim, Eun-Young, Aradi, Daniel, Fernandez-Cadenas, Israel, Horenstein, Richard B., Lee, Ming Ta Michael, Whaley, Ryan M., Montaner, Joan, Gensini, Gian Franco, Cleator, John H., Chang, Kiyuk, Holmvang, Lene, Hochholzer, Willibald, Roden, Dan M., Winter, Stefan, Altman, Russ B., Alexopoulos, Dimitrios, Kim, Ho-Sook, Déry, Jean-Pierre, Gawaz, Meinrad, Bliden, Kevin, Valgimigli, Marco, Marcucci, Rossella, Campo, Gianluca, Schaeffeler, Elke, Dridi, Nadia P., Wen, Ming-Shien, Shin, Jae Gook, Simon, Tabassome, Fontana, Pierre, Giusti, Betti, Geisler, Tobias, Kubo, Michiaki, Trenk, Dietmar, Siller-Matula, Jolanta M., ten Berg, Jurriën M., Gurbel, Paul A., Hulot, Jean-Sebastien, Mitchell, Braxton D., Schwab, Matthias, Ritchie, Marylyn DeRiggi, Klein, Teri E., Shuldiner, Alan R.

“…The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke…”
Get full text

Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults by Jiang, Xi-Ling, Samant, Snehal, Lewis, Joshua P., Horenstein, Richard B., Shuldiner, Alan R., Yerges-Armstrong, Laura M., Peletier, Lambertus A., Lesko, Lawrence J., Schmidt, Stephan

“…Clopidogrel (Plavix®), is a widely used antiplatelet agent, which shows high inter-individual variability in treatment response in patients following the…”
Get full text

Genome-wide association analysis of common genetic variants of resistant hypertension by El Rouby, Nihal, McDonough, Caitrin W., Gong, Yan, McClure, Leslie A., Mitchell, Braxton D., Horenstein, Richard B., Talbert, Robert L., Crawford, Dana C., Gitzendanner, Matthew A., Takahashi, Atsushi, Tanaka, Toshihiro, Kubo, Michiaki, Pepine, Carl J., Cooper-DeHoff, Rhonda M., Benavente, Oscar R., Shuldiner, Alan R., Johnson, Julie A.

“…Resistant hypertension (RHTN), defined as uncontrolled blood pressure (BP) ≥ 140/90 using three or more drugs or controlled BP (<140/90) using four or more…”
Get full text

Genetic Variation in PEAR1 Is Associated With Platelet Aggregation and Cardiovascular Outcomes by Lewis, Joshua P, Ryan, Kathleen, O’Connell, Jeffrey R, Horenstein, Richard B, Damcott, Coleen M, Gibson, Quince, Pollin, Toni I, Mitchell, Braxton D, Beitelshees, Amber L, Pakzy, Ruth, Tanner, Keith, Parsa, Afshin, Tantry, Udaya S, Bliden, Kevin P, Post, Wendy S, Faraday, Nauder, Herzog, William, Gong, Yan, Pepine, Carl J, Johnson, Julie A, Gurbel, Paul A, Shuldiner, Alan R

“…BACKGROUND—Aspirin or dual antiplatelet therapy with aspirin and clopidogrel is a standard therapy for patients who are at increased risk for cardiovascular…”
Get full text

Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response by Backman, Joshua D, O’Connell, Jeffrey R, Tanner, Keith, Peer, Cody J, Figg, William D, Spencer, Shawn D, Mitchell, Braxton D, Shuldiner, Alan R, Yerges-Armstrong, Laura M, Horenstein, Richard B, Lewis, Joshua P

“…Clopidogrel is one of the most commonly used therapeutics for the secondary prevention of cardiovascular events in patients with acute coronary syndromes…”
Get full text

CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study by McDonough, Caitrin W, McClure, Leslie A, Mitchell, Braxton D, Gong, Yan, Horenstein, Richard B, Lewis, Joshua P, Field, Thalia S, Talbert, Robert L, Benavente, Oscar R, Johnson, Julie A, Shuldiner, Alan R

“…The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant…”
Get full text

The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study by Mitchell, Braxton D., PhD, McArdle, Patrick F., PhD, Shen, Haiqing, PhD, Rampersaud, Evadnie, PhD, Pollin, Toni I., PhD, Bielak, Lawrence F., DDS, MPH, Jaquish, Cashell, PhD, Douglas, Julie A., PhD, Roy-Gagnon, Marie-Hélène, PhD, Sack, Paul, MD, Naglieri, Rosalie, MD, Hines, Scott, MD, Horenstein, Richard B., MD, Chang, Yen-Pei C., PhD, Post, Wendy, MD, MS, Ryan, Kathleen A., MPH, Brereton, Nga Hong, MS, RD, Pakyz, Ruth E., BS, MT, ASCD, Sorkin, John, MD, PhD, Damcott, Coleen M., PhD, O'Connell, Jeffrey R., PhD, Mangano, Charles, BA, RDMS, Corretti, Mary, MD, Vogel, Robert, MD, Herzog, William, MD, Weir, Matthew R., MD, Peyser, Patricia A., PhD, Shuldiner, Alan R., MD

“…Background The etiology of cardiovascular disease (CVD) is multifactorial. Efforts to identify genes influencing CVD risk have met with limited success to…”
Get full text

Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers by Horenstein, Richard B., Madabushi, Rajnikanth, Zineh, Issam, Yerges-Armstrong, Laura M., Peer, Cody J., Schuck, Robert N., Figg, William Douglas, Shuldiner, Alan R., Pacanowski, Michael A.

“…Carriers of two copies of the loss‐of‐function CYP2C19*2 variant convert less clopidogrel into its active metabolite, resulting in diminished antiplatelet…”
Get full text

The ABCG8 G574R Variant, Serum Plant Sterol Levels, and Cardiovascular Disease Risk in the Old Order Amish by Horenstein, Richard B, Mitchell, Braxton D, Post, Wendy S, Lütjohann, Dieter, von Bergmann, Klaus, Ryan, Kathleen A, Terrin, Michael, Shuldiner, Alan R, Steinle, Nanette I

“…OBJECTIVE—To determine whether long-term exposure to moderate elevations in plasma plant sterol levels increases risk for atherosclerosis. METHODS AND…”
Get full text